Company profile
FAETH THERAPEUTICS, INC.
NASDAQ:FTHBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SAPANISERTIB | phase2 | — | 11 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05275673 | phase2 | terminated | 2022-07-21 | 2023-01-24 | Faeth Therapeutics | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer |
| NCT05300048 | phase1 | terminated | 2022-04-22 | 2025-04-30 | Faeth Therapeutics | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations |
| NCT06463028 | phase2 | recruiting | 2024-12-12 | 2028-09-01 | Faeth Therapeutics | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer |
| NCT07558733 | phase1_2 | recruiting | 2026-04-22 | 2029-05-01 | Faeth Therapeutics | Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer |
FDA applications (0)
No records yet.